Bonnie A. Avery, Ph.D., joined the College of Pharmacy as a clinical professor of pharmaceutics in January 2017. In general, she is a broadly trained analytical chemist whose research focuses in the areas of physical pharmaceutics, analytical method development and validation and pre-clinical pharmacokinetics. For over 20 years, the majority of her research has centered on novel compound method development and validation. Within the past 10 years, she has extended the boundaries of her research to include pre-clinical pharmacokinetics. She has developed skills in areas including, but not limited to, basic in vivo pharmacokinetic studies in rats and mice, in vitro liver microsomal stability, in situ liver perfusion assays, protein binding, determination of blood/brain ratios, Pgp studies and drug tissue accumulation studies. In collaboration with groups in medicinal chemistry and natural product drug discovery, she has successfully managed pharmacokinetic research on over 50 novel compounds including antimalarials, neuropeptide FF ligands, opioid ligands, sigma receptor ligand/probes and anticancer compounds. She has successfully garnered contract pharmacokinetic research from various companies on drugs such as a paclitaxel pro-drug, synthetic thiazolidinedione, CoQ10, nicotinamide riboside and novel epothilone D analogs. In addition to her personal research interests, she serves as the laboratory director of the UF Translational Drug Development Core. Bonnie A. Avery, Ph.D., joined the College of Pharmacy as a clinical professor of pharmaceutics in January 2017. In general, she is a broadly trained analytical chemist whose research focuses in the areas of physical pharmaceutics, analytical method development and validation and pre-clinical pharmacokinetics. For over 20 years, the majority of her research has centered on novel compound method development and validation. Within the past 10 years, she has extended the boundaries of her research to include pre-clinical pharmacokinetics. She has developed skills in areas including, but not limited to, basic in vivo pharmacokinetic studies in rats and mice, in vitro liver microsomal stability, in situ liver perfusion assays, protein binding, determination of blood/brain ratios, Pgp studies and drug tissue accumulation studies. In collaboration with groups in medicinal chemistry and natural product drug discovery, she has successfully managed pharmacokinetic research on over 50 novel compounds including antimalarials, neuropeptide FF ligands, opioid ligands, sigma receptor ligand/probes and anticancer compounds. She has successfully garnered contract pharmacokinetic research from various companies on drugs such as a paclitaxel pro-drug, synthetic thiazolidinedione, CoQ10, nicotinamide riboside and novel epothilone D analogs. In addition to her personal research interests, she serves as the laboratory director of the UF Translational Drug Development Core.

Biochemistry